LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: Transitional Care in Anorectal Malformation and Hirschsprung's Disease: A Systematic Review of Challenges and Solutions.

    Plascevic, Josip / Shah, Shaneel / Tan, Yew-Wei

    Journal of pediatric surgery

    2023  Band 59, Heft 6, Seite(n) 1019–1027

    Abstract: Background: The literature on transitional care in anorectal malformation (ARM) and Hirschsprung's disease (HD) is diverse and heterogeneous. There is a lack of standards and guidelines specific to transitional care in these conditions. We aim to ... ...

    Abstract Background: The literature on transitional care in anorectal malformation (ARM) and Hirschsprung's disease (HD) is diverse and heterogeneous. There is a lack of standards and guidelines specific to transitional care in these conditions. We aim to establish and systematically categorize challenges and solutions related to colorectal transition care.
    Methods: Systematic review of qualitative studies from MEDLINE, EMBASE, PubMed and Scopus databases (2008-2022) was conducted to identify the challenges and solutions of healthcare transition specific to ARM and HD. Thematic analyses are reported with reference to patient, healthcare provider and healthcare system.
    Results: Sixteen studies from 234 unique articles were included. Fourteen themes related to challenges and solutions, each, are identified. Most challenges identified are patient related. The key challenges pertain to: (1) patient's lack of understanding of their disorder, resulting in over-reliance on the pediatric surgical team and reluctance towards transitioning to adult services; (2) a lack of education and awareness among adult colorectal surgeons in caring for pediatric colorectal conditions and inadequate communication between pediatric and adult teams; and (3) a lack of structured transition program and joint-clinic to meet the needs of the transitioning patients. The key solutions are: (1) fostering young adult patient's autonomy and independence; (2) conducting joint pediatric-adult transition clinics; and (3) ensuring a structured and coordinated transition program is available using a standardized guideline.
    Conclusion: A comprehensive framework related to barriers and solutions for pediatric colorectal transition is established to help benchmark care quality of transitional care services.
    Level of evidence: IV.
    Type of study: Systematic review without meta-analysis.
    Mesh-Begriff(e) Humans ; Hirschsprung Disease/therapy ; Anorectal Malformations/therapy ; Transition to Adult Care
    Sprache Englisch
    Erscheinungsdatum 2023-11-02
    Erscheinungsland United States
    Dokumenttyp Systematic Review ; Journal Article
    ZDB-ID 80165-3
    ISSN 1531-5037 ; 0022-3468
    ISSN (online) 1531-5037
    ISSN 0022-3468
    DOI 10.1016/j.jpedsurg.2023.10.066
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Is arrival by ambulance a risk factor for myocardial infarction in emergency department patients with cardiac sounding chest pain?

    Murray, James / Raja, Edwin Almaraj / Plascevic, Josip / Jacunski, Mark / Cooper, Jamie G

    Emergency medicine journal : EMJ

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-04-22
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2040124-3
    ISSN 1472-0213 ; 1472-0205
    ISSN (online) 1472-0213
    ISSN 1472-0205
    DOI 10.1136/emermed-2023-213643
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions

    Bantounou, Maria / Plascevic, Josip / Galley, Helen F.

    Antioxidants. 2022 Mar. 10, v. 11, no. 3

    2022  

    Abstract: Melatonin, an indoleamine derived from tryptophan and produced in the pineal gland and other tissues [ ... ] ...

    Abstract Melatonin, an indoleamine derived from tryptophan and produced in the pineal gland and other tissues [...]
    Schlagwörter antioxidants ; melatonin ; pineal body ; tryptophan
    Sprache Englisch
    Erscheinungsverlauf 2022-0310
    Erscheinungsort Multidisciplinary Digital Publishing Institute
    Dokumenttyp Artikel
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox11030532
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  4. Artikel: Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions.

    Bantounou, Maria / Plascevic, Josip / Galley, Helen F

    Antioxidants (Basel, Switzerland)

    2022  Band 11, Heft 3

    Abstract: Melatonin, an indoleamine derived from tryptophan and produced in the pineal gland and other tissues [ ... ]. ...

    Abstract Melatonin, an indoleamine derived from tryptophan and produced in the pineal gland and other tissues [...].
    Sprache Englisch
    Erscheinungsdatum 2022-03-10
    Erscheinungsland Switzerland
    Dokumenttyp Editorial
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox11030532
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.

    Bantounou, Maria A / Plascevic, Josip / MacDonald, Lewis / Wong, Man Chun / O'Connell, Neasa / Galley, Helen F

    Current urology

    2023  Band 17, Heft 4, Seite(n) 271–279

    Abstract: Background: Bladder cancer is the 10th most common cancer globally. The majority of bladder cancers are urothelial carcinomas (UCs), which, if locally advanced or metastatic, carry poor long-term prognosis. Cancer cells can evade the immune system by ... ...

    Abstract Background: Bladder cancer is the 10th most common cancer globally. The majority of bladder cancers are urothelial carcinomas (UCs), which, if locally advanced or metastatic, carry poor long-term prognosis. Cancer cells can evade the immune system by expressing the programmed cell death ligand 1 protein (PD-L1). Programmed cell death ligand 1 protein binds to programmed cell death protein 1 (PD-1) on T cells, inhibiting their antitumor action. Bladder tumor cells also overexpress nectin-4, a cell adhesion polypeptide that contributes to metastasis, worsening prognosis. Current platinum-based chemotherapy treatments are suboptimal. This review aimed to assess novel treatments for locally advanced or metastatic UC that specifically target PD-L1 or nectin-4, namely, the PD-1 inhibitor pembrolizumab and the anti-nectin-4 antibody-drug conjugate enfortumab vedotin (EV).
    Materials and methods: Relevant English-language peer-reviewed articles and conference abstracts from the last 5 years were identified through MEDLINE and EMBASE database searches. A narrative review was performed, with key results outlined below.
    Results: Pembrolizumab was demonstrated to be superior to chemotherapy as a second-line treatment for platinum-unresponsive participants in the KEYNOTE-045 trial, resulting in its Food and Drug Administration (FDA) approval. Enfortumab vedotin therapy resulted in superior outcomes compared with chemotherapy in the EV-301 trial, resulting in FDA approval for its use for patients with locally advanced or metastatic UC who had previously undergone treatment with platinum-based chemotherapy and PD-1/PD-L1 inhibitors. Positive preliminary results for pembrolizumab and EV combination therapy have led to FDA approval in patients with locally advanced or metastatic UC who are not eligible for platinum chemotherapy.
    Conclusions: Pembrolizumab and EV represent novel treatment options for patients with locally advanced or metastatic UC with documented superior outcomes and tolerability as compared with standard chemotherapy.
    Sprache Englisch
    Erscheinungsdatum 2023-05-05
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2253664-4
    ISSN 1661-7657 ; 1661-7649
    ISSN (online) 1661-7657
    ISSN 1661-7649
    DOI 10.1097/CU9.0000000000000204
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

    Bantounou, Maria Anna / Sardellis, Panagiotis / Thuemmler, Rosa / Black Boada, Daniel / Kaczmarek, Justyna / Mahmood, Ribeya / Plascevic, Josip / Philip, Sam

    Diabetes, obesity & metabolism

    2023  Band 26, Heft 2, Seite(n) 710–720

    Abstract: Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium-glucose co-transporter-1 and -2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the ... ...

    Abstract Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium-glucose co-transporter-1 and -2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the risk of further renal events, with an emphasis on those with previous renal impairment.
    Methods: Embase, Medline, CENTRAL and Scopus were searched from their inception until 24 April 2023 for randomized controlled trials that reported estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE). The Cochrane risk of bias 2 tool was used. Mean difference, relative risk (RR) and 95% confidence intervals were estimated (PROSPERO: CRD42023425583).
    Results: Fourteen studies were included in this review (n = 17 574 participants; intervention n = 9312, control n = 8262). The median follow-up was 24.5 (Q1 = 15.25, Q3 = 28) months. Four studies recruited participants with renal impairment; baseline eGFR ranged from 23.8 to 50.5 mL/min/1.73m
    Conclusions: Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre-existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.
    Mesh-Begriff(e) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Renal Insufficiency ; Kidney ; Albumins ; Symporters ; Glucose ; Sodium
    Chemische Substanzen (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (6B4ZBS263Y) ; Sodium-Glucose Transporter 2 Inhibitors ; Albumins ; Symporters ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
    Sprache Englisch
    Erscheinungsdatum 2023-11-29
    Erscheinungsland England
    Dokumenttyp Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15364
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang